- Home
- AFMD vs BLRX Comparison
AFMD vs BLRX Comparison
Compare AFMD & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AFMD
- BLRX
- Stock Information
- Founded
- AFMD 2000
- BLRX 2003
- Country
- AFMD Germany
- BLRX Israel
- Employees
- AFMD N/A
- BLRX N/A
- Industry
- AFMD Biotechnology: Pharmaceutical Preparations
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- AFMD Health Care
- BLRX Health Care
- Exchange
- AFMD Nasdaq
- BLRX Nasdaq
- Market Cap
- AFMD 14.5M
- BLRX 12.2M
- IPO Year
- AFMD 2014
- BLRX 2011
- Fundamental
- Price
- AFMD $0.72
- BLRX $2.92
- Analyst Decision
- AFMD Strong Buy
- BLRX Strong Buy
- Analyst Count
- AFMD 5
- BLRX 2
- Target Price
- AFMD $13.50
- BLRX $53.00
- AVG Volume (30 Days)
- AFMD 86.2K
- BLRX 25.8K
- Earning Date
- AFMD 04-08-2025
- BLRX 03-31-2025
- Dividend Yield
- AFMD N/A
- BLRX N/A
- EPS Growth
- AFMD N/A
- BLRX N/A
- EPS
- AFMD N/A
- BLRX N/A
- Revenue
- AFMD $6,287,085.00
- BLRX $28,940,000.00
- Revenue This Year
- AFMD N/A
- BLRX N/A
- Revenue Next Year
- AFMD $225.65
- BLRX N/A
- P/E Ratio
- AFMD N/A
- BLRX N/A
- Revenue Growth
- AFMD N/A
- BLRX 502.92
- 52 Week Low
- AFMD $0.70
- BLRX $2.85
- 52 Week High
- AFMD $8.95
- BLRX $37.20
- Technical
- Relative Strength Index (RSI)
- AFMD 30.95
- BLRX 34.77
- Support Level
- AFMD $0.85
- BLRX $3.01
- Resistance Level
- AFMD $0.89
- BLRX $3.61
- Average True Range (ATR)
- AFMD 0.05
- BLRX 0.21
- MACD
- AFMD -0.01
- BLRX 0.02
- Stochastic Oscillator
- AFMD 22.75
- BLRX 9.21
About AFMD Affimed N.V.
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The Company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.